^
    Back
    Association details:
    Biomarker:MYC rearrangement + BCL2 rearrangement
    Cancer:Diffuse Large B Cell Lymphoma
    Drug:cytarabine (DNA synthesis inhibitor, DNA-directed DNAP inhibitor) +
    methotrexate (Dihydrofolic acid reductase inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C3 – Early Trials
    Source:
    ASH 2018
    Title:

    Young High Risk Patients with MYC/BCL2 Double Hit Lymphoma, BCL2+ and/or Germinal Centre B-Cell like Diffuse Large B-Cell Lymphoma Benefit from Dose-Dense Chemoimmunotherapy Including Early CNS Prophylaxis: Analysis of Data from the Nordic Lymphoma Group CRY-04 and Chic Trials

    Published date:
    11/01/2018
    Excerpt:
    In CRY-04 study, patients were treated with six courses of R-CHOEP14 followed by HD-Mtx and HD-Ara-C...when treatment interaction was tested, MYC/BCL2 double hit status (DHL; 13%) predicted poor outcome among patients treated with CRY-04 regimen compared with patients who received CHIC regimen (4-y PFS; 38% vs 78%, p=0.086).
    Secondary therapy:
    EPOCH-R
    DOI:
    10.1182/blood-2018-99-120057